Analyst Price Target is $12.00
▲ +700.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 700.00% upside from the last price of $1.50.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Aeglea BioTherapeutics. This Buy consensus rating has held steady for over two years.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More